- Trial phase
- Approved
- Time to market
- Already approved and commercially marketed (FDA full approval granted May 25, 2023; initial EUA December 22, 2021).
- Why 3/10
- Nirmatrelvir (Paxlovid) is already FDA-approved and commercially marketed with no pending regulatory decision or pivotal readout in the next 12 months; the patent litigation overhang was resolved in June 2026. As one of many products in Pfizer's diversified portfolio, its declining sales trajectory does not constitute a binary catalyst for the stock.
Nirmatrelvir (Paxlovid) is already approved and commercialized by Pfizer; there is no upcoming binary catalyst for this drug. The key overhang was the Enanta patent litigation, which was resolved in Pfizer's favor in June 2026. Watch Pfizer's quarterly earnings for Paxlovid sales trends, which have been declining as COVID-19 transitions to an endemic phase.
Price Chart
Executive Summary
Nirmatrelvir is the active pharmaceutical ingredient in Pfizer's (PFE) oral COVID-19 antiviral Paxlovid (co-packaged with ritonavir). It is a fully FDA-approved, commercially marketed drug that inhibits the SARS-CoV-2 main protease. The filing hint pointed to Enanta Pharmaceuticals (ENTA) because Enanta sued Pfizer for patent infringement over nirmatrelvir, but the Federal Circuit affirmed invalidation of Enanta's patent on June 23, 2026, removing that litigation risk for Pfizer. Paxlovid sales have been declining as COVID-19 becomes endemic, with Pfizer guiding combined COVID product revenue of roughly $4-5 billion for 2026. For Pfizer, a diversified pharma giant, nirmatrelvir is one of many products and not a binary value driver.
How It Works
Nirmatrelvir is an oral antiviral pill that blocks the SARS-CoV-2 virus's main protease (an enzyme the virus needs to replicate). By inhibiting this enzyme, the drug stops the virus from multiplying inside human cells. It is co-administered with a low dose of ritonavir, which slows the breakdown of nirmatrelvir in the body, keeping it active longer. The combination is taken as a course of pills over five days.
Trial Status
Nirmatrelvir (Paxlovid) received FDA Emergency Use Authorization in December 2021 and full FDA approval in May 2023 for treatment of mild-to-moderate COVID-19 in high-risk adults. It is widely prescribed and has been studied in multiple real-world evidence analyses covering over 700,000 patients. Supplemental sNDA filings continue for label updates (e.g., sNDA 217188/s016, s017 in 2026).
The Two-Sided Case
Upcoming Catalysts
- Pfizer quarterly earnings reports (next: Q4 2026) for Paxlovid sales updates
- Any FDA label expansions or supplemental approvals for broader patient populations
- Seasonal COVID-19 waves that could drive demand
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ENANTA PHARMACEUTICALS INC 8-K ENTA ·Originating report